Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip

Inclusion Criteria: * Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions * Patients 40 to 80 years of age, inclusive, on the day of consent * Body Mass Index (BMI) ≤ 40 kg/m\^2 * Has a documented clinical diagnosis of unilateral or bilateral hip OA for at least six months * Kellgren-Lawrence (KL) Grade 2 or 3 in the index hip as confirmed by local read of X-ray obtained during Screening or ≤ 6 months of Screening visit * Has clinically significant pain in the index hip Exclusion Criteria: * Has a history of hypersensitivity to triamcinolone acetonide, PLGA or lidocaine * Is receiving anticoagulants (including warfarin, dabigatran, rivaroxaban, apixaban or low molecular weight heparin, ritonavir or cobicistat) * Has had any previous surgery on the index hip * Presence of surgical hardware or other foreign body in the index hip * Has a history of infection of the index hip * Has a diagnosis of other disorders in the index hip that can cause pain * Has received any intra-articular injection in the index hip of corticosteroids, investigational (including FX006) or marketed (including Zilretta®) within the 3 months prior to Screening * Has had trauma to the index hip in the past 3 months requiring immobilization * Has a history or evidence of active or latent systemic fungal or mycobacterial infection (including tuberculosis), or of ocular herpes simplex * Has within the past 3 months received co…